Company intelligence / Profile preview

PRM Pharma, LLC

Conshohocken, Pennsylvania, United Statesprmpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

PRM Pharma specializes in developing lower doses of established prescription medicines. Their approach leverages the FDA's 505(b)(2) New Drug Application process to deliver new, lower-dose products efficiently. Their past success includes the development of 12.5 mg hydrochlorothiazide (Microzide®), which is currently one of the most prescribed antihypertensive products in the United States[1].

Therapeutic areas: Cardiovascular
Modalities: Small molecules (lower-dose formulations of established pharmaceuticals)
Industry: Biotech

Drug pipeline

1 asset

chlorthalidone

Commercial

Indications: Hypertension

Beyond the preview

Go deeper on PRM Pharma, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRM Pharma, LLC.

Explore the full profile